



2500 Meadowpine Blvd.  
Unit 202, Mississauga, ON L5N 6C4  
Ph: (416) 669-9392  
Email: [ir@sirebioscience.com](mailto:ir@sirebioscience.com)  
[www.sirebioscience.com](http://www.sirebioscience.com)

## Sire Bioscience Announces Update on June 30, 2020 Q3 Interim Filing

**Toronto, Ontario, August 28, 2020 – Sire Bioscience Inc. (“SIRE”) (CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (“Sire” or the “Company”)** announces that the Company is continuing to work diligently to file its interim financial statements for the third quarter ended June 30, 2020 by October 15, 2020 pursuant to BC Instrument 51-517 *Temporary Exemption from Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to August 31, 2020* (“**BCI 51-517**”).

The Company will be relying on the temporary exemption pursuant to BCI 51-517 in respect to the following provisions:

- the requirement to file interim financial statements for the nine months ended June 30, 2020 (the “**Financial Statements**”) within 60 days after the end of the Company's interim period as required by section 4.4(b) of National Instrument 51-102 *Continuous Disclosure* (“**NI 51-102**”);
- the requirement to file management discussion and analysis (the “**MD&A**”) for the period covered by the Financial Statements within 60 days after the end of the Company's interim period as required by section 5.1(2) of NI 51-102; and
- the requirement to file certifications of the Financial Statements (the “**Certificates**” and together with the Financial Statements, the “**Interim Filings**”) pursuant to section 5.1 of National Instrument 52-109 *Certification of Disclosure in Issuer's Annual and Interim Filings* and section 4.4(b) [being the filing deadline for interim financial statements] of NI 51-102.

The Company confirms that there have been no material developments, other than those disclosed through news releases and Form 7 *Monthly Progress Reports* filed on the Company's profile with the Canadian Securities Exchange, since the filing of its condensed interim consolidated financial statements for the six months ended March 31, 2020.

Additionally, the Company advises that management and other insiders of the Company are subject to a trading black-out policy as described, in principle, in section 9 of National Policy 11-207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.

### About Sire Bioscience Inc.

SIRE's principal business activity is to engage in the investment, production of, development of hemp, CBD and non-CBD products. SIRE has its wholly-owned facility in Leamington, Ontario. The land parcel includes 50 acres of prime horticultural land, with a 160,000 sq. ft. facility of combined greenhouse and indoor space. SIRE's goal is to become a vertically integrated CPG life science company with its "House of Brands" offering.

SIRE is headquartered in Mississauga, Ontario and is managed by a group of successful entrepreneurs who have extensive experience in the areas of consumer packaged goods, manufacturing, logistics, and distribution.

### FOR INFORMATION, CONTACT:

#### Sire Bioscience Inc.

E: [ir@sirebioscience.com](mailto:ir@sirebioscience.com)

*The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.*